
|Articles|January 27, 2021
Supplements and Featured Publications
- Value-Based Agreements in Rare Disease: Focus on Hereditary Amyloid Transthyretin Amyloidosis
Value-Based Agreements in Rare Disease: Focus on Hereditary Amyloid Transthyretin Amyloidosis
Advertisement
The American Journal of Managed Care® hosted a scientific interchange titled “Value-Based Agreements in Rare Disease” on September 30, 2020. This publication highlights key discussion points and insights from this event.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Once-Monthly Maridebart Cafraglutide Shows Up to 16% Weight Loss
2
ASH 2025 Offers Data That Could Make Novel Therapies More Accessible
3
52-Week VERIFY Data Show Rusfertide Brings Sustained Responses in PV
4
In CLL, Fixed-Duration Venetoclax Combos Are Equal to Continuous Ibrutinib in Head-to-Head Comparison
5














































